Could dopamine be a silent killer? Critical Care 2006;11:302.
Shock was defined as a haemodynamic compromise necessitating the administration of vasopressor catecholamines and septic shock the presence of shock plus infection. Patients were followed until death, hospital discharge, or for 60 days, whichever came first. Differences in ICU, hospital, and 30d mortality were determined dependent on whether a subject received dopamine, with secondary analysis by dobutamine, epinephrine, or norepinephrine use.
Results: The intensive care unit mortality rate for shock was 38.3% and 47.4% for septic shock. Of patients in shock, 375 (35.4%) received dopamine (dopamine group) and 683 (64.6%) never received dopamine. Age, gender, Simplified Acute Physiology Score II, and Sequential Organ Failure Assessment score were comparable between the two groups. The dopamine group had higher intensive care unit (42.9% vs. 35.7%, p=.02) and hospital (49.9% vs. 41.7%, p=.01) mortality rates. A Kaplan-Meier survival curve showed diminished 30 day-survival in the dopamine group (log rank=4.6, p=.032).
In a multivariate analysis with intensive care unit outcome as the dependent factor, age, cancer, medical admissions, higher mean Sequential Organ Failure Assessment score, higher mean fluid balance, and dopamine administration were independent risk factors for intensive care unit mortality in patients with shock.
Conclusión: This observational study suggests that dopamine administration may be associated with increased mortality rates in shock. There is a need for a prospective study comparing dopamine with other catecholamines in the management of circulatory shock.
Archivo: Bajar artículo completo [clic aquí]
